Literature DB >> 34105513

Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition.

Felice Gragnano1, Alessandro Spirito, Noé Corpataux, Lukas Vaisnora, Roberto Galea, Giuseppe Gargiulo, George C M Siontis, Fabien Praz, Jonas Lanz, Michael Billinger, Lukas Hunziker, Stefan Stortecky, Thomas Pilgrim, Sarah Bär, Yasushi Ueki, Davide Capodanno, Philip Urban, Stuart J Pocock, Roxana Mehran, Dik Heg, Stephan Windecker, Lorenz Räber, Marco Valgimigli.   

Abstract

BACKGROUND: The identification of bleeding risk factors in patients undergoing percutaneous coronary intervention (PCI) is essential to inform subsequent management. Whether clinical presentation per se affects bleeding risk after PCI remains unclear. AIMS: We aimed to assess whether clinical presentation per se predisposes to bleeding in patients undergoing PCI and if the Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria perform consistently in acute (ACS) and chronic (CCS) coronary syndrome patients.
METHODS: Consecutive patients undergoing PCI from the Bern PCI Registry were stratified by clinical presentation. Bleeding events at one year were compared in ACS versus CCS patients, and the originally defined ARC-HBR criteria were assessed.
RESULTS: Among 16,821 patients, 9,503 (56.5%) presented with ACS. At one year, BARC 3 or 5 bleeding occurred in 4.97% and 3.60% of patients with ACS and CCS, respectively. After adjustment, ACS remained associated with higher BARC 3 or 5 bleeding risk (adjusted HR 1.21, 95% CI: 1.01-1.43; p=0.034), owing to non-access site-related occurrences, which accrued mainly within the first 30 days after PCI. The ARC-HBR score had lower discrimination among ACS compared with CCS patients, and its performance slightly improved when ACS was computed as a minor criterion.
CONCLUSIONS: ACS presentation per se predicts one-year major bleeding risk after PCI. The ARC-HBR score discrimination appeared lower in ACS than CCS, and its overall performance improved numerically when ACS was computed as an additional minor risk criterion.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34105513     DOI: 10.4244/EIJ-D-21-00181

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  11 in total

Review 1.  Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention.

Authors:  Francesco Pelliccia; Felice Gragnano; Vincenzo Pasceri; Arturo Cesaro; Marco Zimarino; Paolo Calabrò
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

2.  Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.

Authors:  Felice Gragnano; Marcel Zwahlen; Pascal Vranckx; Dik Heg; Kurt Schmidlin; Christian Hamm; Philippe Gabriel Steg; Giuseppe Gargiulo; Eugene P McFadden; Yoshinobu Onuma; Ply Chichareon; Edouard Benit; Helge Möllmann; Luc Janssens; Sergio Leonardi; Aleksander Zurakowski; Alessio Arrivi; Robert Jan Van Geuns; Kurt Huber; Ton Slagboom; Paolo Calabrò; Patrick W Serruys; Peter Jüni; Marco Valgimigli; Stephan Windecker
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

3.  Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI.

Authors:  Hao-Yu Wang; Bo Xu; Chen-Xi Song; Chang-Dong Guan; Li-Hua Xie; Yan-Yan Zhao; Zhong-Xing Cai; Sheng Yuan; Ke-Fei Dou
Journal:  J Interv Cardiol       Date:  2022-01-13       Impact factor: 2.279

4.  Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Zhong-Liang Dai; Yi-Feng Song; Ya Tian; Yin Li; Miao Lin; Juan Lin; Qi Wang; Ping Wang; Wen-Li Gao
Journal:  BMC Cardiovasc Disord       Date:  2021-10-01       Impact factor: 2.298

5.  Prevalence of High Bleeding Risk among Hospitalized Suspected NSTEMI Patients.

Authors:  Henri Kesti; Henna Mäkinen; Kalle Mattila; Samuli Jaakkola; Mikko Lintu; Pekka Porela
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

6.  Hyperuricemia is associated with an increased prevalence of ventricular tachycardia and fibrillation in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.

Authors:  Xianqing Hu; Shenwen Fu; Saibin Wang
Journal:  BMC Cardiovasc Disord       Date:  2022-04-26       Impact factor: 2.174

7.  A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization.

Authors:  Raffaele De Caterina; Paolo Calabrò; Gianluca Campo; Roberta Rossini; Simona Giubilato
Journal:  J Clin Med       Date:  2022-04-08       Impact factor: 4.964

8.  Perioperative coronary artery spasm after off-pump coronary artery bypass grafting in the non-manipulated coronary artery.

Authors:  Yunpeng Bai; Yiming Bai; Nan Jiang; Qingliang Chen; Zhigang Guo
Journal:  BMC Cardiovasc Disord       Date:  2022-04-12       Impact factor: 2.298

9.  Performance of PRECISE-DAPT and Age-Bleeding-Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients.

Authors:  Liang Dong; Cao Lu; Chen Wensen; Chen Fuzhong; Muhammad Khalid; Dong Xiaoyu; Li Guangjuan; Qian Yanxia; Zhang Yufeng; Liu Xinjian; Chen Leilei; Wang Junhong
Journal:  Front Cardiovasc Med       Date:  2022-07-08

10.  Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention.

Authors:  Amir Faour; Nicholas Collins; Trent Williams; Arshad Khan; Craig P Juergens; Sidney Lo; Darren L Walters; Derek P Chew; John K French
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.